PharmaCyte Biotech, Inc.
PMCB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001157075
No open-market purchases or sales by PharmaCyte Biotech, Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $586.2K in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding PharmaCyte Biotech, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 35 | 33 | −2 |
| Shares | 3.92M | 4.98M | +1.06M (+27.1%) |
| Value | $8.79M | $12.0M | +$3.17M (+36.0%) |
New holders (2)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Csenge Advisory Group | 200,104 | $480.0K | 0.04% |
| Davy Global Fund Management Ltd | 38,771 | $93.0K | 0.02% |
Sold out (4)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Citadel Advisors LLC | 31,696 | $72.0K |
| FNY Investment Advisers, LLC | 15,290 | $34.0K |
| Blue Bell Private Wealth Management, LLC | 2 | $0 |
| Heritage Financial Services, LLC | 67 | $0 |